Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation
Inflammatory Bowel Diseases · 01.07.2026 · 32 (7) · 1313-1320
DOI: 10.1093/ibd/izag038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.03.2026. Verfasst von Pavithra Ramakrishnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
In patients with inflammatory bowel disease (IBD), Clostridioides difficile infection (CDI) presents with clinical features indistinguishable from the underlying disease. Sequential polymerase chain reaction (PCR) and enzyme immunoassay (EIA) testing reduce overdiagnosis; however, discordant results create management uncertainties.
Methods
We conducted a retrospective cohort study of IBD patients with positive C. difficile PCR testing at 2 institutions between April 2022 and December 2023. Patients were stratified by EIA toxin (TOX) results. Demographic, clinical, laboratory, and therapeutic data were extracted, and outcomes assessed included CDI-directed therapy or escalation of IBD treatment.
Results
Of 575 IBD patients tested, 117 met inclusion criteria. Among them, 79% (93/117) were PCR+/TOX− and 21% (24/117) were PCR+/TOX+. PCR+/TOX+ patients had significantly higher CRP (98 vs 6 mg/L, P = .005). PCR+/TOX− patients had more severe underlying IBD and higher rates of steroid use (48% vs 21%, P = .02) and were less likely to receive CDI treatment (72% vs 96%, P = .01) but were significantly more likely to require IBD therapy escalation (54% vs 25%, P = .004). Multivariable analysis showed PCR+/TOX− status (odds ratio [OR], 3.2; P = .045) and moderate-to-severe endoscopic disease within 1 year of testing (OR, 5.6; P = .0007) were significant predictors of IBD treatment escalation.
Conclusions
Elevated CRP may help distinguish true CDI in IBD. PCR+/TOX+ patients typically respond to CDI-directed therapy, whereas PCR+/TOX− patients more often require escalation of IBD treatment, suggesting noninfectious inflammation as the primary driver of symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, United States.
- Research department , MNGI Digestive Health, Minneapolis, MN 55413, United States.
- Gastroenterology Section, Veterans Affairs Medical Center, Minneapolis, MN 55417, United States.
- Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN 55455, United States.
ORCID-Profile: Pavithra Ramakrishnan
Zitieren
APA
Ramakrishnan, P., Campbell, J., Moutsoglou, D., Ghai, M., Shmidt, E., & Vaughn, B. P. (2026). Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation. Inflammatory Bowel Diseases, 32(7), 1313-1320. https://doi.org/10.1093/ibd/izag038
Vancouver
Ramakrishnan P, Campbell J, Moutsoglou D, Ghai M, Shmidt E, Vaughn BP. Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation. Inflammatory Bowel Diseases. 2026;32(7):1313-1320. doi:10.1093/ibd/izag038
BibTeX
@article{Ramakrishnan2026,
author = {Ramakrishnan, Pavithra and Campbell, James and Moutsoglou, Daphne and Ghai, Megan and Shmidt, Eugenia and Vaughn, Byron P},
title = {Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {7},
pages = {1313--1320},
doi = {10.1093/ibd/izag038}
}
EUVIMED